Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Updating Pricing on Brand to Generic Drugs are Timing and Inventory Issues for Payers and Providers

September 16, 2008

Analysis of:Medicare overpaid on drugs with new generics, report says | www.latimes.com

Payers in the private sector have historically tried to get providers to pay the generic price for branded multisource products using maximum allowable cost (MAC) terminology in their contracts as soon as the branded drugs have a generic source. This has caused problems for providers that still have branded products in thier inventory. The government is now trying to follow the private sectors example and force providers to pay for the generic drugs bypassing the 2-month delay used to help providers deplete their inventory of the branded products.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS